This study aims to develop, train, and validate a machine learning-based prediction model (PROTEGER) to provide treatment decision recommendations for older adults diagnosed with solid tumor cancers. The study has a two-phase observational design: a retrospective cohort using anonymized data from an oncogeriatric telecommittee to train the predictive model, followed by a prospective multicenter cohort across Chile, Peru, and Brazil. Information from Comprehensive Geriatric Assessments (CGA), treatment decisions, and 3- and 6-month clinical outcomes will be collected to evaluate and validate the decision-support platform's performance in assisting oncology teams.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age 65 years or older.
* Diagnosis of solid tumor cancer.
* Must have been evaluated and followed up by a local oncology team.
* Signed Informed Consent Form (ICF) applied in accordance with the local ethics committee.
* Must have undergone a Comprehensive Geriatric Assessment (CGA).
Exclusion Criteria:
\- Patients who are unable or unwilling to consent to providing information will be excluded.
Primary outcome measure(s)
Predictive Accuracy of the PROTEGER Machine Learning Model — Up to 6 months post-enrollment. Discrimination performance of the machine learning predictive model in recommending oncogeriatric treatment decisions (standard treatment, dose-adjusted treatment, or supportive care/no treatment) based on Comprehensive Geriatric Assessment (CGA) data, measured by the Area Under the Receiver Operating Characteristic Curve (AUC-ROC), with scores ranging from 0.5 (no discrimination/chance) to 1.0 (perfect discrimination).
Trial sites (2)
Facility
City
Region
Status
BR192 HCOR - Hospital do Coração
São Paulo
São Paulo
HIAE - Hospital Israelita Albert Einstein
São Paulo
São Paulo
More Latin American Cooperative Oncology Group trials in Brazil
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
